Article
Oncology
Hajime Yonezawa, Makoto Ohno, Hiroshi Igaki, Yasuji Miyakita, Masamichi Takahashi, Yukie Tamura, Satoshi Shima, Yuko Matsushita, Koichi Ichimura, Yoshitaka Narita
Summary: The study evaluated the outcomes of re-irradiation combined with bevacizumab for patients with recurrent high-grade gliomas who had progressed after bevacizumab treatment and found the treatment to be feasible. Patients with a higher Karnofsky performance status tended to have longer survival and progression-free survival times.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Karan S. Dixit, Sean Sachdev, Christina Amidei, Priya Kumthekar, Tim J. Kruser, Vinai Gondi, Sean Grimm, Rimas Lukas, Martin Kelly Nicholas, Steven J. Chmura, Angela J. Fought, Minesh Mehta, Jeffrey J. Raizer
Summary: This study demonstrates that re-irradiation with bevacizumab and temozolomide is a safe and effective salvage treatment for patients with bevacizumab-refractory high-grade glioma. Patients further from their initial radiotherapy may derive greater benefit from this regimen.
JOURNAL OF NEURO-ONCOLOGY
(2021)
Article
Oncology
Solmaz Sahebjam, Peter A. Forsyth, Nam D. Tran, John A. Arrington, Robert Macaulay, Arnold B. Etame, Christine M. Walko, Theresa Boyle, Edwin N. Peguero, Michael Jaglal, Sepideh Mokhtari, Heiko Enderling, Natarajan Raghunand, Tyra Gatewood, Wendy Long, Jennifer L. Dzierzeski, Brittany Evernden, Timothy Robinson, Melissa C. Wicklund, Sungjune Kim, Zachary J. Thompson, Dung-Tsa Chen, Prakash Chinnaiyan, Hsiang-Hsuan Michael Yu
Summary: The combination of hypofractionated stereotactic irradiation (HFSRT) with pembrolizumab and bevacizumab is generally safe and well tolerated in patients with recurrent high-grade gliomas. In patients without prior bevacizumab treatment, 83% showed complete or partial response, while in bevacizumab-resistant patients, 62% achieved partial response. This treatment approach warrants further investigation for its potential in improving outcomes for high-grade glioma patients.
Review
Biochemistry & Molecular Biology
Jacob P. Fisher, David C. Adamson
Summary: The standard of care for high-grade gliomas includes surgical resection, radiation therapy, and temozolomide, which have improved patient survival rates. Besides temozolomide, there are several other FDA-approved treatments for HGG, with tumor treatment fields being the only one shown to significantly improve survival rates.
Review
Neurosciences
Alice Giotta Lucifero, Sabino Luzzi
Summary: High-grade gliomas (HGGs) exhibit resilience against conventional chemotherapies due to their heterogeneous genetic landscape, adaptive phenotypic changes, and immune escape mechanisms. Innovative immunotherapies have been developed to counteract the immunosuppressive capability of gliomas, with active immunotherapies including systemic temozolomide, monoclonal antibodies, and vaccines, and adoptive immunotherapies showing potential treatment options for relapsing gliomas. Further research is needed to assess the efficacy of these immuno-based approaches in treating high-grade gliomas.
Article
Oncology
Alonso La Rosa, Alonso N. Gutierrez, Yazmin Odia, Michael W. McDermott, Manmeet S. Ahluwalia, Minesh P. Mehta, Rupesh Kotecha
Summary: We report a case of a multi-recurrent high-grade glioma patient who was successfully treated with a novel radiation therapy technique, temporally modulated pulsed proton re-irradiation (TMPPR), after multiple salvage strategies. TMPPR allows enhanced tumor cell death and increased normal cell sublethal repair by delivering radiation dose in smaller subfractions as pulses using proton therapy. The treatment achieved a complete response (CR) with minimal treatment-related toxicities and no neurocognitive function deterioration observed.
NEURO-ONCOLOGY ADVANCES
(2023)
Article
Oncology
Robert L. Hollis, Alison M. Meynert, Caroline O. Michie, Tzyvia Rye, Michael Churchman, Amelia Hallas-Potts, Ian Croy, W. Glenn McCluggage, Alistair R. W. Williams, Clare Bartos, Yasushi Iida, Aikou Okamoto, Brian Dougherty, J. Carl Barrett, Ruth March, Athena Matakidou, Patricia Roxburgh, Colin A. Semple, D. Paul Harkin, Richard Kennedy, C. Simon Herrington, Charlie Gourley
Summary: This study characterized the molecular landscape of HGSOC and identified specific molecular events associated with clinical prognosis and treatment response. The results showed that patients with BRCA2 gene mutations and EMSY gene overexpression had longer survival and higher chemotherapy response rate. Patients with CCNE1 gene gain had lower proportion of stage IV cases and shorter survival, but no significant difference in treatment response.
CLINICAL CANCER RESEARCH
(2022)
Review
Medicine, General & Internal
Andrea Franson, Brandon L. McClellan, Maria Luisa Varela, Andrea Comba, Mohammad Faisal Syed, Kaushik Banerjee, Ziwen Zhu, Nazareno Gonzalez, Marianela Candolfi, Pedro Lowenstein, Maria Graciela Castro
Summary: The development of novel immunotherapies for central nervous system tumors, particularly high-grade gliomas, is progressing rapidly. Understanding the genetic drivers and tumor microenvironment of these tumors holds promise for a more targeted therapeutic approach. This review focuses on the tumor microenvironment and immunotherapy development in high-grade gliomas, with a specific focus on glioblastoma multiforme and pediatric gliomas.
FRONTIERS IN MEDICINE
(2022)
Article
Oncology
Lei She, Lin Su, Chao Liu
Summary: The purpose of this study was to evaluate the safety, tolerability, and efficacy of a combination of BEV and re-RT for the treatment of rGBM. The results showed that this combination therapy was safe, tolerable, and effective in rGBM patients. Additionally, gross total resection prior to re-RT and selective concurrent temozolomide further improved patient PFS and OS.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Yuhang Wang, Ruifeng Liu, Qiuning Zhang, Meng Dong, Dandan Wang, Junru Chen, Yuhong Ou, Hongtao Luo, Kehu Yang, Xiaohu Wang
Summary: High-grade gliomas remain difficult to treat despite standard therapy. Charged particle beams, especially carbon ion beams, have the potential to improve treatment outcomes. This systematic review assessed the safety, efficacy, and dosimetry of carbon-ion or proton radiotherapy for high-grade gliomas. The analysis of eleven eligible articles showed that charged particle radiotherapy was effective with manageable side effects. Carbon ion boost appeared to be superior to proton boost, but dose-escalation using proton boost was associated with severe brain necrosis. Further randomized control trials are needed, along with systemic therapeutic options.
RADIATION ONCOLOGY
(2023)
Review
Clinical Neurology
James L. Ross, Jose Velazquez Vega, Ashley Plant, Tobey J. MacDonald, Oren J. Becher, Dolores Hambardzumyan
Summary: Significant progress has been made in elucidating the origin and genomic landscape of childhood high-grade brain tumors over the past decade. However, clinical trials for children with gliomas have historically been ineffective due to a lack of consideration for the fundamental biological differences between pediatric and adult tumors. Little is known about the dynamic tumor immune microenvironment in pediatric high-grade gliomas despite expanded knowledge on cellular mechanisms driving tumor progression.
Article
Oncology
Ana Cloquell, Isidro Mateo, Stefano Gambera, Marti Pumarola, Ramon Alemany, Javier Garcia-Castro, Ana Judith Perise-Barrios
Summary: This study demonstrates that dCelyvir is safe and effective in canine rostrotentorial high-grade gliomas. ICOCAV17 was detected in peripheral blood in nine dogs, and a correlation between the ICOCAV17 particles and anti-canine adenovirus (CAV) antibodies was observed. ICOCAV17 was detected in 3/9 tumor tissues after necropsies.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Medicine, General & Internal
Valentina Di Ruscio, Andrea Carai, Giada Del Baldo, Maria Vinci, Antonella Cacchione, Evelina Miele, Sabrina Rossi, Manila Antonelli, Sabina Barresi, Massimo Caulo, Giovanna Stefania Colafati, Angela Mastronuzzi
Summary: Molecular investigations are crucial in the diagnosis and treatment decision of infantile high-grade gliomas (iHGG) with different molecular profiles, and can help replace toxic chemotherapy with targeted therapy.
Review
Oncology
Hsiao P. J. Voon, Lee H. Wong
Summary: Pediatric high grade gliomas (HGG) are lethal and untreatable tumors. Recent studies have revealed that mutations in chromatin proteins, particularly H3.3 and its associated chaperone complex (ATRX), are a hallmark feature of pediatric HGGs. This article reviews the current literature on the normal functions of the ATRX/H3.3 complex and how they are disrupted by oncogenic mutations, as well as discusses the potential of targeting chromatin and DNA in clinical trials and pre-clinical models.
FRONTIERS IN ONCOLOGY
(2023)
Review
Genetics & Heredity
Katarzyna B. Leszczynska, Chinchu Jayaprakash, Bozena Kaminska, Jakub Mieczkowski
Summary: DIPG is a challenging cancer to treat, mainly affecting children at the brainstem with potential epigenetic abnormalities. Targeting epigenetic dysregulation with drug treatments may have a therapeutic effect in treating pHGG expressing H3K27M.
FRONTIERS IN GENETICS
(2021)
Article
Oncology
Galina Farina Fischer, Detlef Bruegge, Nicolaus Andratschke, Brigitta Gertrud Baumert, Davide Giovanni Bosetti, Francesca Caparrotti, Evelyn Herrmann, Alexandros Papachristofilou, Susanne Rogers, Lucia Schwyzer, Daniel Rudolf Zwahlen, Thomas Hundsberger, Paul Martin Putora
Summary: Due to limited evidence on the utility of postoperative radiotherapy for meningiomas, treatment strategies vary considerably among clinical experts depending on the clinical setting, even in a small country like Switzerland. Clear majorities were identified for postoperative radiotherapy in WHO grade III meningiomas and against radiotherapy for hemispheric grade I meningiomas outside critical locations.
Article
Oncology
A. M. Zeitlberger, P. M. Putora, S. Hofer, P. Schucht, D. Migliorini, A. F. Hottinger, U. Roelcke, H. Laeubli, P. Spina, O. Bozinov, M. Weller, M. C. Neidert, T. Hundsberger
Summary: In Switzerland, NGS is frequently used in adult patients with glioblastoma in Neuro-Oncology centres, particularly in younger, fitter patients who are not suitable for standard therapy. Despite its limited impact on treatment decisions, the application of NGS remains common in these centres.
JOURNAL OF NEURO-ONCOLOGY
(2022)
Article
Oncology
Ulrich Roelcke, Lucia Schwyzer, Anna Maria Zeitlberger, Thomas Hundsberger
Summary: This article introduces a clinical toolkit for the evaluation of symptom burden, performance status, and neurological function in glioblastoma patients. Through a prospective follow-up evaluation of 50 patients, the authors found that composite score, fatigue score, NIH-SS, and KPS were suitable biomarkers for evaluating symptom burden and disease progression. The clinical toolkit is feasible in routine clinical practice and can reflect changes in the disease course of glioblastoma patients.
Article
Oncology
Leonie Mueller-Jensen, Sarah Zierold, Judith M. Versluis, Wolfgang Boehmerle, Petra Huehnchen, Matthias Endres, Raphael Mohr, Annette Compter, Christian U. Blank, Tim Hagenacker, Friedegund Meier, Lydia Reinhardt, Anja Gesierich, Martin Salzmann, Jessica C. Hassel, Selma Ugurel, Lisa Zimmer, Patricia Banks, Lavinia Spain, Jennifer A. Soon, Tomohiro Enokida, Makoto Tahara, Katharina C. Kaehler, Ruth Seggewiss-Bernhardt, Catriona Harvey, Georgina V. Long, Florian Schoeberl, Louisa von Baumgarten, Thomas Hundsberger, Max Schlaak, Lars E. French, Samuel Knauss, Lucie M. Heinzerling
Summary: Immune checkpoint inhibitor-induced encephalitis (ICI-iE) is a rare but life-threatening toxicity that shows variable clinical features and can be distinguished from herpes simplex virus (HSV-1) encephalitis and anti-leucine-rich glioma-inactivated 1 (anti-LGI1) encephalitis. Cerebrospinal fluid (CSF) analysis is the most important diagnostic tool for ICI-iE, and early treatment is crucial to prevent complications and death.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Clinical Neurology
Alexis Paul Romain Terrapon, Marie Kruger, Thomas Hundsberger, Marian Christoph Neidert, Oliver Bozinov
Summary: Randomized controlled studies are necessary to prove the prognosis and quality of life.
NEUROSURGERY CLINICS OF NORTH AMERICA
(2023)
Article
Multidisciplinary Sciences
Leonie Mueller-Jensen, Sarah Zierold, Judith M. Versluis, Wolfgang Boehmerle, Petra Huehnchen, Matthias Endres, Raphael Mohr, Annette Compter, Christian U. Blank, Tim Hagenacker, Friedegund Meier, Lydia Reinhardt, Anja Gesierich, Martin Salzmann, Jessica C. Hassel, Selma Ugurel, Lisa Zimmer, Patricia Banks, Lavinia Spain, Jennifer A. Soon, Tomohiro Enokida, Makoto Tahara, Katharina C. Kaehler, Ruth Seggewiss-Bernhardt, Catriona Harvey, Georgina Long, Florian Schoeberl, Louisa von Baumgarten, Thomas Hundsberger, Max Schlaak, Lars E. French, Samuel Knauss, Lucie M. Heinzerling
Summary: Cancer immunotherapy with immune checkpoint inhibitors (ICIs) has greatly improved the outcome of many malignancies in the past decade. However, it has also led to an increase in neurological immune-related adverse events (irAE), particularly ICI-induced encephalitis (ICI-iE), which can have severe consequences. This study aims to define the characteristics of ICI-iE and distinguish it from other causes of encephalitis, in order to raise awareness and improve diagnosis and management.
Article
Oncology
Markus Joerger, Thomas Hundsberger, Simon Haefliger, Roger von Moos, Andreas F. Hottinger, Thomas Kaindl, Marc Engelhardt, Michalina Marszewska, Heidi Lane, Patrick Roth, Anastasios Stathis
Summary: The purpose of this study was to evaluate the safety, tolerability and antitumor activity of lisavanbulin as a 48-hour intravenous infusion at the recommended Phase 2 dose. The study included patients with ovarian, fallopian-tube, or primary peritoneal cancer as well as glioblastoma patients. The results showed that lisavanbulin was well tolerated and exhibited some antitumor activity in patients.
INVESTIGATIONAL NEW DRUGS
(2023)
Article
Behavioral Sciences
Carole Jenny, Jacoba van der Linde, Thomas Hundsberger, Philip J. Broser
Summary: The study aimed to investigate the maturation of the peripheral nervous system by analyzing the cross-sectional area of the sciatic nerve during the first 2 years of life. Using high-resolution ultrasound imaging, the sciatic nerve of 52 children aged 0 days to 10 years was examined, and a significant correlation between age and nerve cross-sectional area was found. A logarithmic growth model was developed to describe the growth rate of the nerve. The study provides normative values for the size of the sciatic nerve in children.
BRAIN AND BEHAVIOR
(2023)
Article
Oncology
C. Schmitt, E. P. Hoefsmit, T. Fangmeier, N. Kramer, C. Kabakci, J. Vera Gonzalez, J. M. Versluis, A. Compter, T. Harrer, H. Mijocevic, S. Schubert, T. Hundsberger, A. M. Menzies, R. A. Scolyer, G. V. Long, L. E. French, C. U. Blank, L. M. Heinzerling
Summary: A study of melanoma patients from three countries found no significant association between previous neurotropic infections and immune checkpoint inhibitor-induced neurological adverse events.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Immunology
Paraskevas Filippidis, Jose Damas, Benjamin Viala, Frederic Assal, Olivier Nawej Tshikung, Philip Tarr, Tobias Derfuss, Michael Oberholzer, Ilijas Jelcic, Thomas Hundsberger, Leonardo Sacco, Matthias Cavassini, Renaud Du Pasquier, Katharine E. A. Darling
Summary: CSF HIV-1 escape occurred in 8.7% of PLWH in Switzerland, and these individuals did not have distinctive clinical or paraclinical characteristics compared to those without escape. Lumbar puncture is therefore necessary for confirming CSF HIV-1 escape.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
(2023)
Meeting Abstract
Clinical Neurology
A. Zeitlberger, P. Putora, S. Hofer, P. Schucht, D. Migliorini, A. Hottinger, U. Roelcke, H. Laubli, P. Spina, O. Bozinov, M. Weller, M. Neidert, T. Hundsberger
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Meeting Abstract
Oncology
Johannes Weller, Thomas Zeyen, Uwe Schlegel, Lazaros Lazaridis, Jan-Michael Werner, Julia Onken, Pia Zeiner, Richard Drexler, Peter Hau, Clemens Seidel, Lucia Grosse, Hans Clusmann, Michael Sabel, Florian Ringel, Josef Pichler, Oliver Grauer, Thomas Hundsberger, Oliver Schnell, Maximilian J. Mair, Martin Uhl, Friederike Schmidt-Graf, Martin Glas, Norbert Galldiks, Meike Unteroberdoerster, Joachim Steinbach, Franz Ricklefs, Mirjam Renovanz, Daniel Ivanov Delev, Merih O. Turgut, Oliver R. Flesch, Debora Cipriani, Matthias Preusser, Sied Kebir, Martin Misch, Roland Goldbrunner, Manfred Westphal, Ghazaleh Tabatabai, Niklas Schaefer, Matthias Schneider, Hartmut Vatter, Frank Giordano, Christina Schaub, Ulrich Herrlinger
Meeting Abstract
Clinical Neurology
J. Zimmermann, C. Rothermundt, T. Hundsberger
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Meeting Abstract
Clinical Neurology
B. Wagner, A. Beuttler, N. Kiriakidis, M. Joerger, R. Kaeufeler, T. Hundsberger
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Meeting Abstract
Clinical Neurology
M. Baldauf, W. Jochum, A. Lauber, T. Hundsberger, M. Brandle
EUROPEAN JOURNAL OF NEUROLOGY
(2022)